Study Summary

GOG 258

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC 3

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

NRG-GY012

NRG-GY012

DESKTOP Trial - Secondary Debulking Surgery

Secondary debulking surgery in recurrent ovarian cancer

PORTEC 2

Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)

RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NRG GY018 - Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

MITO-7 and weekly chemotherapy in ovarian cancer

Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer

BEATcc

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc)